Skip to main content
HemaSphere logoLink to HemaSphere
. 2022 Feb 15;6(3):e698. doi: 10.1097/HS9.0000000000000698

Correction Notice: Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A

PMCID: PMC8849417  PMID: 35187409

Since the publication of the article entitled “Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A” (HemaSphere. 2022;6(2):e679), the authors have requested a spelling correction for a co-author’s name. The first/given name of Simon M. Walker was erroneously listed as Sikon in the manuscript’s original publication. This has now been adjusted.

The changes have been made online: https://journals.lww.com/hemasphere/Fulltext/2022/02000/Modeling_Benefits,_Costs,_and_Affordability_of_a.5.aspx


Articles from HemaSphere are provided here courtesy of Wiley

RESOURCES